 |
Patented Products KLab has 90% market share of the complete Methocarbamol market in India. KLab is the only company marketing Prenoxdiazine in India. |
|
||||||||
|
KLAB is marketing its generic products in the various
therapeutic segments through its sales team. KLAB products
are manufactured in WHO-GMP facilities. KLAB has contract
manufacturing agreement with Indian and International
companies for some of their products.
KLab has focus on Chiral synthesis. Chiral synthesis has
become important in research and industry due to the
pathways increased need for enantiopure chiral durgs. This
leads to strong and fast growing range of new chiral
building blocks, chiral catalysts and the increased use of
chiral biotransformation in organic synthesis.
|
KLab is one of the pioneers in India inKLAB is a pioneer in
the Indian Oncology formulations market. It has one of the
widest range of Oncology formulations, which are
manufactured at KLAB owned WHO-GMP approved facility at
Thane, Mumbai.
LAB manufactures tablets, capsules, powder and liquid injectables. KLAB's oncology products are now registered in more than 30 countries in Africa, Latin America, CIS and South East Asia. In India KLAB has a dedicated Oncology task force which covers Oncologists and Oncology Institutions across the length and breadth of India. Further, KLAB supplies finished ONCO formulations to a large number of Indian Companies. |
|||||||||
|
KLab has a dedicated oncology facility for manufacturing
various APIs. KLab also has a separate sterile powder
manufacturing facility.
|
||||||||||
